Category: Media Coverage

Note: When you click on media articles below, a new page will open indicating that you are leaving the Genprex, Inc. website and entering a third-party website not affiliated with Genprex Inc. or any of its affiliates. No information contained in a linked site has been endorsed or approved by Genprex, Inc. and Genprex, Inc. is not responsible for the content of such third-party websites.

UPMC Children’s Hospital Researchers Working On ‘Groundbreaking’ Procedure To Cure Diabetes

February 12, 2020

Thirty million Americans are living with diabetes and hoping someday to be cured. That day could come sooner than expected, thanks to a team of researchers at UPMC Children’s Hospital of Pittsburgh.

Genprex to Focus on Developing Immunogene Therapy, Start Lung Cancer Trials This Year

February 6, 2020

Genprex said that after receiving the US Food and Drug Administration’s fast track designation last month for its immunogene therapy Oncoprex in combination with the EGFR tyrosine kinase inhibitor (TKI) osimertinib (AstraZeneca’s Tagrisso), the clinical-stage gene therapy company is prioritizing development of this therapy combination for EGFR-mutated non-small cell lung cancer.

Genprex Wins FDA Fast Track Status for its Oncoprex Therapy in Combination with AstraZeneca’s Tagrisso

January 23, 2020

Genprex Inc (NASDAQ:GNPX) announced that the US Food and Drug Administration has granted Fast Track Designation for its Oncoprex immunogene therapy to treat lung cancer.

FDA Grants Fast Track Designation to Oncoprex Combination for NSCLC

January 23, 2020

Oncoprex in combination with Tagrisso received fast track designation from the Food and Drug Administration to treat patients with non-small cell lung cancer.

FDA Grants Fast Track Designation to Gene Therapy Combination in EGFR-Mutant NSCLC

January 23, 2020

The FDA has granted a Fast Track Designation to the immune-gene therapy Oncoprex in combination with the EGFR inhibitor osimertinib (Tagrisso) for the treatment of patients with EGFR-mutant non–small cell lung cancer (NSCLC) who have progressed after treatment with osimertinib alone, according to a press release from Genprex, Inc, developer of the therapeutic.